Capitalizator.

Capitalize Yourself: Right Data. Real Growth.

Company Analysis

GLUE Insider Trading

Monte Rosa Therapeutics, Inc. | Biological Products, (No Diagnostic Substances)

Comprehensive Trading Performance Summary

The investment history of corporate insiders at Monte Rosa Therapeutics, Inc. provides a unique lens into the internal conviction of the company's leadership. By analyzing SEC Form 4 filings, investors can track how directors and officers are allocating their own capital. High-conviction buying often signals that management believes the current market price significantly undervalues future growth prospects, while strategic selling might occur for personal liquidity or portfolio diversification. Monitoring these shifts in ownership is essential for understanding the alignment between management and shareholders in the Biological Products, (No Diagnostic Substances) sector.

Last 7 Days
$0
Buys
$0
Sells
Last 30 Days Trend
$0
Buys
$0
Sells

Transactions on Chart

Open Full Chart
Filing Date Trade Date Reporting Person Relationship Type Price Qty Total, $ Owned After Change, %
2026-01-10 00:05 2026-01-07 Warmuth Markus Director, Officer - President & CEO SELL $23.49 5,466 $128,373 618,937 -0.9%
2026-01-06 00:06 2026-01-05 Nickson Philip Officer - Chief Business & Legal Officer SELL $15.17 3,155 $47,861 60,845 -4.9%
2026-01-06 00:05 2026-01-05 Champoux Jennifer Officer - Chief Operating Officer SELL $15.17 2,629 $39,882 62,371 -4.0%
2026-01-06 00:04 2026-01-05 Dunn Edmund Officer - Principal Accounting Officer SELL $15.17 1,039 $15,762 22,693 -4.4%
2026-01-06 00:04 2026-01-05 Warmuth Markus Director, Officer - President & CEO SELL $15.17 10,135 $153,748 624,403 -1.6%
2026-01-06 00:04 2026-01-05 Janku Filip Officer - Chief Medical Officer SELL $15.17 3,155 $47,861 75,026 -4.0%
2026-01-06 00:04 2026-01-05 Townson Sharon Officer - Chief Scientific Officer SELL $15.17 3,155 $47,861 67,845 -4.4%
2025-06-04 23:15 2025-06-03 Dunn Edmund Officer - Principal Accounting Officer SELL $4.45 2,062 $9,174 23,732 -8.0%
2025-03-26 01:32 2025-03-24 Leo Chandra P. Director BUY $5.84 10,000 $58,383 10,000 +100.0%
2024-10-30 23:35 2024-10-28 Versant Venture Capital VI, L.P. 10% owner SELL $9.44 157,895 $1,491,034 1,573,453 -9.1%
2024-09-24 23:40 2024-09-20 Versant Venture Capital VI, L.P. 10% owner SELL $6.53 1,132,566 $7,395,203 5,099,336 -18.2%
2024-09-14 01:44 2024-09-11 Versant Venture Capital VI, L.P. 10% owner SELL $6.00 567,213 $3,404,809 6,231,902 -8.3%
2024-07-09 23:15 2024-07-05 Dunn Edmund Officer - Principal Accounting Officer SELL $3.83 1,610 $6,166 13,944 -10.4%
2024-06-05 23:10 2024-06-03 Dunn Edmund Officer - Principal Accounting Officer SELL $4.04 1,207 $4,876 15,554 -7.2%
2021-07-01 01:09 2021-06-28 Yang Rick 10% owner BUY $19.00 1,050,000 $19,950,000 7,692,298 +15.8%
2021-07-01 01:08 2021-06-28 Walker Paul Edward 10% owner BUY $19.00 1,050,000 $19,950,000 7,692,298 +15.8%
2021-07-01 01:08 2021-06-28 Sonsini Peter W. 10% owner BUY $19.00 1,050,000 $19,950,000 7,692,298 +15.8%
2021-07-01 01:07 2021-06-28 SANDELL SCOTT D 10% owner BUY $19.00 1,050,000 $19,950,000 7,692,298 +15.8%
2021-07-01 01:06 2021-06-28 Mathers Edward T 10% owner BUY $19.00 1,050,000 $19,950,000 7,692,298 +15.8%
2021-07-01 01:06 2021-06-28 MAKOWER JOSHUA 10% owner BUY $19.00 1,050,000 $19,950,000 7,692,298 +15.8%
2021-07-01 01:05 2021-06-28 Makhzoumi Mohamad 10% owner BUY $19.00 1,050,000 $19,950,000 7,692,298 +15.8%
2021-07-01 01:04 2021-06-28 Landsman Liza 10% owner BUY $19.00 1,050,000 $19,950,000 7,692,298 +15.8%
2021-07-01 01:02 2021-06-28 Florence Anthony A. Jr. 10% owner BUY $19.00 1,050,000 $19,950,000 7,692,298 +15.8%
2021-07-01 01:02 2021-06-28 Chang Carmen 10% owner BUY $19.00 1,050,000 $19,950,000 7,692,298 +15.8%
2021-07-01 01:01 2021-06-28 Behbahani Ali Director, 10% owner BUY $19.00 1,050,000 $19,950,000 7,692,298 +15.8%
2021-07-01 01:00 2021-06-28 BASKETT FOREST 10% owner BUY $19.00 1,050,000 $19,950,000 7,692,298 +15.8%
2021-07-01 00:59 2021-06-28 New Enterprise Associates 17, L.P. 10% owner BUY $19.00 1,050,000 $19,950,000 7,692,298 +15.8%
2021-07-01 00:05 2021-06-28 Bolzon Bradley J PhD Director, 10% owner BUY $19.00 157,895 $3,000,005 2,097,938 +8.1%
2021-07-01 00:00 2021-06-28 Versant Venture Capital VI, L.P. 10% owner BUY $19.00 157,895 $3,000,005 2,097,938 +8.1%
2021-06-30 23:08 2021-06-28 Cormorant Asset Management, LP Other BUY $19.00 600,000 $11,400,000 3,202,200 +23.1%
SHOW ENTRIES
1-30 OF 30

How to Interpret $GLUE Trades

Not every insider transaction in Monte Rosa Therapeutics, Inc. is a signal for immediate action. Professional investors look for "cluster buying"—when multiple executives simultaneously purchase $GLUE shares on the open market. It is crucial to distinguish between scheduled sales (under Rule 10b5-1) and voluntary increases in ownership, which demonstrate management’s true conviction that the stock is undervalued.

Data Source & Accuracy for GLUE

Insider activity data for Monte Rosa Therapeutics, Inc. is streamed in real-time directly from the SEC EDGAR system. We analyze raw Form 4 filings, filtering out technical adjustments and complex derivative transactions. This provides a transparent view of how ownership structure is evolving in $GLUE, allowing you to follow the capital of those with the most intimate knowledge of the company.

UNDERSTANDING THE DATA

FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.

TRADE DATE: The actual day the insider executed the purchase or sale in the market.

INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.

OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.

CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.

TRADE TYPES DEFINITIONS

BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.

SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.

OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.